FGFR4 and prostate carcinoma: Our meta-analysis showed the evidence that FGFR4 Arg388 allele was associated with an increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism could be a marker for prostate cancer development and progression.